Trizivir is a drug owned by Viiv Healthcare Co. It is protected by 6 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 14, 2018. Details of Trizivir's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US6294540 (Pediatric) | Carbocyclic nucleoside hemisulfate and its use in treating viral infections |
Nov, 2018
(6 years ago) |
Expired
|
| US6294540 | Carbocyclic nucleoside hemisulfate and its use in treating viral infections |
May, 2018
(7 years ago) |
Expired
|
|
US5905082 (Pediatric) | Crystalline oxathiolane derivatives |
Nov, 2016
(8 years ago) |
Expired
|
|
US6417191 (Pediatric) | Synergistic combinations of zidovudine, 1592U89 and 3TC |
Sep, 2016
(9 years ago) |
Expired
|
| US5905082 | Crystalline oxathiolane derivatives |
May, 2016
(9 years ago) |
Expired
|
| US6417191 | Synergistic combinations of zidovudine, 1592U89 and 3TC |
Mar, 2016
(9 years ago) |
Expired
|
While patent expiration is one way of estimating the generic date of a drug, if a patent gets
invalidated somehow, the
generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal
pitfalls. Given
below are details of the litigation history of Trizivir and ongoing
litigations to
help you estimate the early arrival of Trizivir generic.
Trizivir's Litigations
Trizivir been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 08, 2015, against patent number US6417191. The petitioner Teva Pharmaceuticals USA, Inc., challenged the validity of this patent, with ViiV Healthcare Co. as the respondent. Click below to track the latest information on how companies are challenging Trizivir's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6417191 | June, 2014 |
Terminated-Settled
(03 Aug, 2015) | ViiV Healthcare Co. | Apotex Corp. |
| US6417191 | January, 2015 |
Institution Denied
(25 Jun, 2015) | ViiV Healthcare Co. et al. | Teva Pharmaceuticals USA, Inc. |
| US6417191 | January, 2015 |
Terminated-Denied
(25 Jun, 2015) | ViiV Healthcare Co. | Teva Pharmaceuticals USA, Inc. |
US patents provide insights into the exclusivity only within the United States, but
Trizivir is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Trizivir's family patents as well as insights into
ongoing legal events
on those patents.
Trizivir's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Trizivir's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 14, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Trizivir Generic API suppliers:
Abacavir Sulfate; Lamivudine; Zidovudine is the generic name for the brand Trizivir. 1 company has already filed for the generic of Trizivir. Check out the entire list of companies who have already received approval for Trizivir's generic
How can I launch a generic of Trizivir before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Trizivir's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Trizivir's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Trizivir -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 300 mg/150 mg/ 300 mg | 22 Mar, 2011 | 1 | 05 Dec, 2013 | 14 May, 2018 | Eligible |
Alternative Brands for Trizivir
Trizivir which is used for treating patients infected with HIV., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||
|---|---|---|---|---|---|---|---|---|
| Agouron Pharms |
| |||||||
| Bristol Myers Squibb |
| |||||||
| Gilead |
| |||||||
| Gilead Sciences Inc |
| |||||||
| Roche |
| |||||||
| Viiv Hlthcare |
| |||||||
About Trizivir
Trizivir is a drug owned by Viiv Healthcare Co. It is used for treating patients infected with HIV. Trizivir uses Abacavir Sulfate; Lamivudine; Zidovudine as an active ingredient. Trizivir was launched by Viiv Hlthcare in 2000.
Approval Date:
Trizivir was approved by FDA for market use on 14 November, 2000.
Active Ingredient:
Trizivir uses Abacavir Sulfate; Lamivudine; Zidovudine as the active ingredient. Check out other Drugs and Companies using Abacavir Sulfate; Lamivudine; Zidovudine ingredient
Treatment:
Trizivir is used for treating patients infected with HIV.
Dosage:
Trizivir is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 300MG BASE;150MG;300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |